





### **Scope of the Meeting**

#### **Expert Consultation on Monitoring and Evaluation of Antimicrobial Resistance (AMR) Interventions**

**DATES:** January 26 – 27, 2017

**VENUE:** Florida International University, 1<sup>st</sup> Street, N.W, Washington DC, Office 440.

The Regional Action Plan on Antimicrobial Resistance (AMR) for the Americas was adopted by the Pan American Health Organization's Directing Council in 2015. The Plan is aligned with the global process initiated by the governing bodies of the World Health Organization, the Food and Agricultural Organization, and Organization of Animal Health (OIE). Following the 68<sup>th</sup> World Health Assembly of the WHO, countries agreed to develop national action plans on AMR consistent with the Global Action Plan, and to implement relevant policies and plans to prevent, control and monitor AMR.

WHO will build global consensus on an approach to AMR monitoring, including monitoring implementation of the GAP and UNGA agreements, with defined measures of impact and outcome, as well as key indicators. It is expected that this expert meeting will contribute to the global process. The discussion will provide inputs to establish and implement a monitoring framework, focused on Latin America and the Caribbean.

The Global Health Consortium at the Florida International University (FIU) provides technical cooperation in the areas of education, policy, and applied research in several global health priorities, such as, antimicrobial surveillance, antimicrobial stewardship, international health, communicable and non-communicable diseases, vaccinations, access to medicines and innovation, health and migration, universal health access and coverage, and climate change and health.

This meeting is the result of joint efforts by the FIU/Global Health Consortium and the PAHO/WHO to provide guidance to countries and other stakeholders on the strategy for monitoring and evaluating interventions aimed at decreasing the impact of and containing AMR.

#### **PURPOSE**

To contribute to the global process of AMR monitoring led by the WHO, from the perspective of the Region of the Americas and its insights.

#### **OBJECTIVES**

- 1. To discuss efficient monitoring and evaluation strategies of AMR national action plans in Latin America and the Caribbean.
- 2. To provide guidance for country capacity building for AMR surveillance, and tools for monitoring and evaluation of AMR containment interventions.
- 3. To develop a preliminary menu of Regional and national indicators for that are consistent with the global process.

### TENTATIVE AGENDA

### January 26, 2017

| 8:30  | Registration.   |                        |  |
|-------|---|------------------------|--|
| 9:00  | Opening session - Objectives - Review of agenda – Nomination of Chairperson.                      | M. Espinal, PAHO/WHO   |  |
|       |   | C. Espinal, FIU        |  |
| 9:15  | Session 1: Introduction. AMR: Global, regional, national action plans – Scope for                 | P. Ramon-Pardo,        |  |
|       | monitoring and evaluation.  | PAHO/WHO               |  |
|       | Defining indicators needed to monitor interventions. Impact, output and process indicators        | V. Walford, WHO HQ     |  |
|       | - for AMR. Discussions from the WHO Strategic Technical Advisory Group.                           |                        |  |
| 9:45  | Session 2: Bases for the development of efficient monitoring and evaluation strategies on         |                        |  |
|       | AMR (national) action plans.  |                        |  |
|       | - Burden of multidrug resistant bacterial infections in low – middle income countries.            | V. Thamlikitkul,       |  |
|       |   | WHO Collaborating      |  |
|       |   | Center on AMR,         |  |
|       |   | Thailand.              |  |
|       | - Impact of regulation on antibiotic sales: challenges and achievements. The experience of Chile. | L. Bavestrello, Chile. |  |
| 10:30 | Coffee Break  |                        |  |

| 11:00 | Session 3: Defining the indicators to monitor interventions.   |                              |   |  |
|-------|--|------------------------------|---|--|
|       | Conscience of Antimicrobial Resistance Accountability (CARA)  Setting national targets to reduce unnecessary antibiotic prescription  Antimicrobial Stewardship Programs: one size does not fit all. Measuring their |                              | H. Gelband, CDDEP D. Hyun, PEW Charitable M.V. Villegas, CIDEIM |  |
|       |  |                              |   |  |
|       |  |                              |   |  |
|       | effectiveness  |                              |   |  |
|       | Role of civil society in monitoring AMR. The experience from the Antibiotic Resistance   |                              | R. Ramachandran, ReAct  |  |
|       | Coalition  |                              |   |  |
| 12:30 | Lunch Break  |                              |   |  |
| 13:30 | ROOM 1 - Session 4: Strategic line1  | ROOM 2 - Session 5:          | ROOM 2 - Session 5: Strategic line 2                            |  |
|       | Improve awareness and understanding of   | Strengthen knowledg          | Strengthen knowledge and scientific grounding                   |  |
|       | antimicrobial resistance through effective   | through surveillance         | and research  |  |
|       | communications, education, and training  | <b>Moderator</b> : M. Galas, | PAHO/WHO  |  |
|       | Moderator: A. P. Celi, Asociación  |                              |   |  |
|       | Panamericana de Infectología   |                              |   |  |
| 15:00 | Coffee Break   | Coffee Break                 |   |  |
| 15:30 | ROOM 1 - Session 6: Strategic line 3   | ROOM 2 - Session 7:          | Strategic line 4  |  |
|       | Reduce the incidence of infections through   | Optimize the use of ar       | ntimicrobial drugs in   |  |
|       | effective sanitation, hygiene, and preventive  | human and animal he          | alth  |  |
|       | measures   | Moderator: A. Dresei         | r, INSP, Mexico.  |  |
|       | <b>Moderator</b> : D. Vanderende, CDC, USA   |                              |   |  |

## 17:00 **End of day 1**

# January 27, 2017

| 9:00  | Session 8: Strategic line 5- Prepare economic arguments for        | Moderator: Anthony So, ReAct  |
|-------|--|-------------------------------|
|       | sustainable investment that takes into account the needs of all    |                               |
|       | countries, and increase investment in new drugs, diagnostic tools, |                               |
|       | vaccines, and other actions  |                               |
| 10:00 |  | Rapporteurs (Sessions 4 to 7) |
|       | Session 9: Plenary discussion                                      |                               |
|       | Presentation of indicators under each strategic line of action     |                               |
| 11:15 | Questions and comments   |                               |
|       | Coffee break   |                               |
| 11:30 | Session 10: Conclusions and recommendations                        | P. Ramon-Pardo, PAHO/WHO      |
| 12:00 | Closing remarks  | C. Espinal, FIU               |
| 12:30 | Lunch  |                               |